. 2022 Feb 24;2(2):102–118. doi: 10.1007/s43657-021-00042-x

Table 1.

Evidence-based recommendations for the use of ¹⁸F-FDG PET at different treatment time points

Time point	Indication	HL^a	DLBCL^a
Pre-treatment PET	Staging	+++	+++
Interim PET	Early response assessment	++	++
End-of-treatment PET	Remission assessment	++	++
PET during follow-up	Disease surveillance	±	±

^a+++: standard of care. ++: standard—depending on therapy regimen. ±: optional—recommended in selected cases, e.g., suspected relapse

FDG fluorodeoxyglucose, PET positron emission tomography, HL Hodgkin’s lymphoma, DLBCL diffuse large B-cell lymphoma